Hair-follicle immune privilege is a locally regulated state that limits immune recognition around important parts of the growing follicle. It is maintained through reduced antigen presentation, local immunoregulatory signals and control of inflammatory immune cells.
In alopecia areata, this protection can become disrupted. Follicular structures then become more visible to the immune system, while cytotoxic T cells and inflammatory signalling interfere with normal hair growth.
Immune-privilege collapse is an important model for understanding alopecia areata. However, it is not the disease’s only mechanism. Genetic susceptibility, immune-cell activation, cytokine signalling and environmental influences may all contribute.
This Journal review explains where follicular immune privilege occurs, how it is maintained, what may happen when it breaks down and why this biology has influenced modern alopecia-areata treatment.
Key Takeaways
- Parts of the growing hair follicle display relative immune privilege. This is especially relevant around the lower portion of the anagen follicle and hair bulb.
- Immune privilege is actively maintained. Reduced MHC expression and local immunoregulatory signals help limit antigen presentation and inappropriate inflammation.
- Alopecia areata involves loss of this protective environment. Increased antigen presentation and inflammatory signalling can expose the growing follicle to immune attack.
- CD8+ NKG2D+ T cells are important participants. IFN-γ, IL-15 and JAK-STAT signalling help sustain the inflammatory process.
- Alopecia areata usually does not destroy the follicle permanently. Follicular stem-cell regions are generally preserved, which makes regrowth possible.
- Regrowth is not guaranteed or necessarily permanent. Alopecia areata can remit, recur or progress despite structurally preserved follicles.
- Immune-mediated hair loss needs the correct diagnosis. Supplements and ordinary growth stimulants do not treat the underlying autoimmune process.
Sudden or Patchy Hair Loss Needs Proper Assessment
Round patches can suggest alopecia areata, but fungal infection, traction, hair pulling and scarring disorders may sometimes produce confusing patterns. Early assessment can help identify when medical referral is required.
What Is Hair-Follicle Immune Privilege?
Immune privilege describes a local tissue environment in which immune recognition and inflammatory responses are restricted compared with ordinary tissue.
The term was first used for sites such as the eye, brain, placenta and testes. Research later demonstrated that parts of the human hair follicle also exhibit relative immune privilege.
This does not mean that the follicle is hidden completely from the immune system or contains no immune cells. Instead, the follicle uses several coordinated mechanisms to reduce the likelihood of a damaging immune response.
Hair-follicle immune privilege is also dynamic. Its strength and location can change with the hair cycle. It is most clearly described around the lower portion of the follicle during anagen, the active growth phase.
Where Does Immune Privilege Occur?
The human hair follicle contains several anatomically and functionally distinct regions. Therefore, it is misleading to describe the entire follicle as one uniformly protected structure.
Two areas are particularly relevant:
- The lower anagen follicle and hair bulb: This region surrounds rapidly proliferating matrix cells and pigment-producing melanocytes. It is the main site discussed in alopecia-areata immune-privilege research.
- The bulge region: This upper follicular area contains epithelial stem cells needed for follicular regeneration. It has its own immune-protective features, including expression of immunoregulatory molecules such as CD200.
In alopecia areata, inflammatory activity usually focuses around the lower anagen follicle. By contrast, several primary cicatricial alopecias target the upper permanent follicle and bulge region. Damage in that location can destroy the stem-cell compartment and lead to permanent loss.
How the Hair Follicle Maintains Immune Privilege
Follicular immune privilege depends on several overlapping mechanisms. No single molecule creates or maintains it by itself.
Reduced antigen presentation
Cells normally use major histocompatibility complex molecules to display antigens to immune cells.
In the lower healthy anagen follicle, MHC class I expression and associated components such as beta-2 microglobulin are relatively reduced. MHC class II expression is also limited.
This lower antigen-presenting activity makes it less likely that follicular antigens will trigger a cytotoxic or helper T-cell response.
Local immunoregulatory signals
The follicular environment contains molecules that can suppress or regulate immune activation. These include:
- Transforming growth factor beta, including TGF-β1 and TGF-β2.
- Alpha-melanocyte-stimulating hormone.
- Interleukin-10.
- Macrophage migration inhibitory factor.
- Programmed death-ligand 1 in relevant follicular compartments.
- Indoleamine 2,3-dioxygenase.
- CD200, particularly in the epithelial stem-cell region.
The relative importance of each molecule can vary by follicular region, hair-cycle phase, experimental model and disease state.
Regulation of natural killer cells and T cells
Healthy follicular signalling also helps control natural killer cells and cytotoxic T cells. When protective signalling weakens, these cells may become activated and participate in follicular inflammation.
Immune privilege should therefore be understood as a controlled local network rather than a physical barrier surrounding the follicle.
Why Is Immune Privilege Important During Anagen?
During anagen, the lower follicle undergoes intense biological activity. Matrix keratinocytes proliferate, melanocytes produce pigment and the follicle continuously generates the hair shaft.
Some follicular proteins and melanogenesis-associated molecules may potentially serve as immune targets in a genetically susceptible person. Reducing antigen presentation and inflammatory activity may help the follicle continue this work without inappropriate immune interference.
However, rapid cell division does not automatically cause immune attack. Healthy tissues throughout the body contain proliferating cells without becoming autoimmune targets.
The importance of immune privilege lies in the follicle’s specialized regulation of immune visibility and local inflammation, not simply in its metabolic rate.
How Can Hair-Follicle Immune Privilege Collapse?
Immune-privilege collapse refers to a shift from a relatively protected follicular environment toward increased immune recognition and inflammation.
Changes described in alopecia areata include:
- Increased MHC class I and class II expression.
- Reduced expression of local immunoregulatory factors.
- Increased production of interferon gamma.
- Increased expression of stress-associated ligands such as MICA.
- Activation and recruitment of CD8+ NKG2D+ cytotoxic T cells.
- Natural killer-cell and mast-cell changes.
- Activation of IL-15 and JAK-STAT signalling.
These processes can reinforce one another. For example, IFN-γ can increase antigen presentation and inflammatory chemokine production. IL-15 can support the survival and activity of cytotoxic lymphocytes. Together, these signals may sustain an inflammatory loop around susceptible follicles.
Figure 1. Immune-privilege collapse around the hair follicle. The supplied article attributes this image to Guo H, Cheng Y, Shapiro J and McElwee K. Confirm the exact figure source and reproduction licence before publication.
What Triggers Immune-Privilege Collapse?
There is no single confirmed trigger for every case of alopecia areata.
Genetic susceptibility plays an important role. Environmental or physiological events may then influence disease onset or recurrence in some people. Reported or suspected factors include:
- Viral and other infections.
- Major psychological or physiological stress.
- Physical injury or local skin inflammation.
- Hormonal or metabolic changes.
- Certain immune-modifying medications.
These associations need careful interpretation. Many people experience infection, stress or trauma without developing alopecia areata. In addition, a stressful event may occur coincidentally before hair loss becomes visible.
It is therefore more accurate to say that potential triggers may interact with genetic and immune susceptibility than to claim that stress or infection directly causes immune-privilege collapse.
Immune-Privilege Breakdown in Alopecia Areata
Alopecia areata is a nonscarring, immune-mediated form of hair loss. It can affect the scalp, beard, eyebrows, eyelashes or other body hair.
In active disease, inflammatory cells may gather around the lower portion of anagen follicles. This is sometimes described histologically as a peribulbar “swarm of bees.” However, this classic pattern is not present in every biopsy or every disease stage.
Research implicates CD8+ NKG2D+ T cells as important effectors. These cells can recognize stress-associated signals around the follicle and produce inflammatory mediators that interrupt normal growth.
Interferon gamma and interleukin-15 are particularly relevant. They activate JAK-STAT pathways and help maintain the autoimmune inflammatory loop.
Figure 2. Immune signalling and immune-privilege collapse in alopecia areata. The supplied article attributes this image to Šutić Udović I and colleagues. Confirm the exact figure, Creative Commons terms and required attribution before publication.
Does Alopecia Areata Destroy Hair Follicles?
In most cases, alopecia areata does not permanently destroy the follicle. The epithelial stem-cell region is generally preserved.
Instead, inflammation disrupts the growth cycle. Affected anagen follicles may enter catagen prematurely, produce dystrophic hairs or remain unable to sustain normal terminal hair production.
This structural preservation explains why regrowth can occur spontaneously or following treatment. Nevertheless, it should not be interpreted as a guarantee.
Alopecia areata can be:
- Limited to one or several patches.
- Diffuse rather than distinctly patchy.
- Persistent or recurrent.
- Extensive across the scalp.
- Associated with complete scalp-hair loss, known as alopecia totalis.
- Associated with loss of hair across the body, known as alopecia universalis.
Long-standing or extensive disease can be more difficult to treat even when follicles have not been replaced by scar tissue.
Why Is Alopecia Areata Often Sudden and Patchy?
Alopecia areata frequently begins with one or more smooth, sharply defined patches. Immune activity may affect groups of susceptible anagen follicles within a localized area, producing an abrupt clinical pattern.
However, not every case is patchy. Alopecia areata can also produce:
- Diffuse thinning.
- A band-like ophiasis pattern around the scalp margin.
- Sudden extensive scalp loss.
- Eyebrow or eyelash loss.
- Beard patches.
- Nail pitting or other nail changes.
Sudden patches are suggestive, but they are not diagnostic by themselves. Tinea capitis, trichotillomania, traction and some scarring alopecias may resemble alopecia areata.
Alopecia Areata Versus Scarring Alopecia
| Feature | Alopecia Areata | Primary Scarring Alopecia |
|---|---|---|
| General classification | Nonscarring immune-mediated alopecia. | Inflammatory alopecia with follicular destruction. |
| Common target area | Lower anagen follicle and hair bulb. | Often the upper permanent follicle and stem-cell region. |
| Follicular openings | Usually preserved. | May be reduced or lost as scarring develops. |
| Regrowth potential | Often possible because follicles remain present. | Limited once follicles have been permanently destroyed. |
| Need for medical assessment | Important for diagnosis, severity assessment and treatment selection. | Urgent assessment is important to limit additional permanent loss. |
The distinction is clinically important. Scalp pain, burning, pustules, marked scale, redness or loss of follicular openings should raise concern for an inflammatory or scarring disorder requiring dermatological evaluation.
How Immune Biology Influences Treatment
Understanding alopecia areata as an immune-mediated disease explains why ordinary vitamins, cosmetic serums and hair-growth products cannot correct the underlying mechanism.
Treatment depends on age, disease extent, duration, affected areas, previous response, medical history and patient preference.
Corticosteroids
Topical, intralesional or systemic corticosteroids may be used in selected patients to reduce inflammatory immune activity. The route depends partly on the extent and location of hair loss.
Topical immunotherapy
Contact immunotherapy may be considered for extensive disease in specialist settings. It deliberately produces an allergic contact reaction that alters local immune activity. It requires professional supervision.
Minoxidil
Minoxidil may support hair growth in some treatment plans, but it does not treat the primary autoimmune mechanism. It is generally an adjunct rather than immune-directed monotherapy for active alopecia areata.
JAK inhibitors
JAK inhibitors interfere with intracellular signalling used by inflammatory cytokines involved in alopecia areata, including pathways influenced by IFN-γ and IL-15.
In the United States, the FDA has approved multiple oral JAK inhibitors for severe alopecia areata in defined age groups. These include:
- Baricitinib for adults with severe alopecia areata.
- Ritlecitinib for adults and adolescents aged 12 years and older with severe alopecia areata.
- Deuruxolitinib for adults with severe alopecia areata.
Regulatory approval and availability differ by country and may change over time.
These medications can produce substantial regrowth in some patients, but they do not work for everyone. They also carry important safety considerations, screening requirements, interactions and monitoring needs.
JAK inhibitors should not be started, stopped or compared casually without a dermatologist or another qualified prescribing clinician.
Does Treatment Restore Immune Privilege?
Researchers sometimes describe successful alopecia-areata treatment as permitting restoration of immune privilege. That may be a useful biological interpretation, but it is not a routine clinical measurement.
Clinicians do not generally biopsy follicles before and after treatment to prove that immune privilege has returned. Instead, treatment response is assessed through:
- Reduction in active hair loss.
- Clinical and trichoscopic signs of reduced disease activity.
- Terminal hair regrowth.
- Improvement in scalp, eyebrow or eyelash involvement.
- Standardized severity measurements such as the SALT score.
- Adverse effects and laboratory monitoring where required.
Therefore, it is more accurate to say that immune-directed treatment can suppress disease activity and allow follicles to resume growth than to promise permanent restoration of immune tolerance.
Clinical Implications for Trichology Practice
A trichologist may help recognize patterns compatible with alopecia areata and distinguish them from ordinary diffuse shedding or androgenetic alopecia.
Assessment may include:
- Onset and speed of hair loss.
- Patch distribution.
- Eyebrow, eyelash, beard and body-hair involvement.
- Nail changes.
- Exclamation-mark hairs or broken hairs.
- Yellow dots, black dots and tapered hairs on trichoscopy.
- Signs of infection or scarring.
- Personal or family history of autoimmune or atopic disease.
However, a trichologist is not automatically a medical doctor. Suspected alopecia areata should be referred appropriately when confirmation, prescription treatment, laboratory investigation or biopsy may be required.
Referral is particularly important when:
- The diagnosis is uncertain.
- Hair loss is rapidly progressing.
- Large areas of the scalp are affected.
- Eyebrows or eyelashes are involved.
- A child develops patchy hair loss.
- There are signs of infection or scarring.
- Systemic or JAK-inhibitor treatment may be considered.
Practical Next Steps
- Check the pattern: Smooth round patches can suggest alopecia areata, but they are not diagnostic by themselves.
- Look beyond the scalp: Eyebrow, eyelash, beard, body-hair and nail changes can be clinically relevant.
- Do not rely on supplements: Nutritional correction will not control an autoimmune follicular attack unless a separate deficiency also exists.
- Watch for scarring signs: Pain, burning, pustules, marked redness or absent follicular openings need prompt medical attention.
- Seek early assessment: Correct classification helps avoid ineffective treatment and unnecessary delay.
Frequently Asked Questions
What does immune privilege mean in a hair follicle?
It describes a locally regulated environment that reduces antigen presentation and inflammatory immune activity around important parts of the follicle. It is relative protection, not complete isolation from the immune system.
Is the entire hair follicle immune privileged?
Not uniformly. Immune-privilege features differ by anatomical region and hair-cycle phase. The lower anagen follicle and the epithelial stem-cell region have distinct protective mechanisms.
What happens when hair-follicle immune privilege collapses?
Antigen presentation and inflammatory signalling may increase. Cytotoxic immune cells can then gather around the follicle and interrupt normal anagen growth. This process is strongly implicated in alopecia areata.
Is immune-privilege collapse the only cause of alopecia areata?
No. It is an important disease model, but alopecia areata is multifactorial. Genetic susceptibility, T-cell activity, cytokine signalling and other immune processes also contribute.
Does stress cause immune-privilege collapse?
Stress is reported as a possible trigger by some patients, and stress biology may influence immune signalling. However, it is rarely possible to prove that a particular stressful event caused an individual case of alopecia areata.
Why does alopecia areata cause patches?
Immune activity can affect localized groups of follicles, producing sharply defined areas of loss. However, alopecia areata may also be diffuse or extensive rather than classically patchy.
Can hair regrow after alopecia areata?
Yes. Regrowth is possible because alopecia areata usually preserves the follicular stem-cell region. Nevertheless, the condition can recur, persist or become extensive, and regrowth is not guaranteed.
Is alopecia areata a scarring alopecia?
No. Alopecia areata is classified as nonscarring. Primary scarring alopecias damage the permanent follicle and can eliminate its capacity to regenerate.
Can vitamins restore hair-follicle immune privilege?
No vitamin or supplement has been established as a treatment that restores follicular immune privilege in alopecia areata. A confirmed nutritional deficiency should still be corrected, but that does not replace immune-directed medical care.
Do JAK inhibitors cure alopecia areata?
No. JAK inhibitors can suppress relevant inflammatory signalling and produce meaningful regrowth in some patients. They are not guaranteed cures, relapse may occur and ongoing treatment may be required.
Does alopecia areata require a biopsy?
Not always. A dermatologist can often diagnose typical alopecia areata through examination and trichoscopy. A biopsy may be considered when the diagnosis is uncertain or another disorder must be excluded.
Not Sure What Type of Hair Loss You Have?
An assessment can help distinguish immune-mediated patchy loss from pattern thinning, telogen effluvium, traction, infection and potentially scarring disease. Medical referral remains essential when alopecia areata or another inflammatory disorder is suspected.
Conclusion
Hair-follicle immune privilege is an actively maintained local state that limits antigen presentation and inflammatory attack around important follicular compartments.
In alopecia areata, this protective environment can break down. Increased MHC expression, IFN-γ and IL-15 signalling, and activation of CD8+ NKG2D+ T cells can disrupt normal anagen growth.
The follicle usually remains structurally present, which explains why regrowth is possible. Still, alopecia areata is heterogeneous and unpredictable. It can resolve, recur, persist or progress.
Immune-privilege collapse is therefore a valuable framework for understanding the disease, but it should not be presented as a complete explanation or a clinically measurable switch.
Correct diagnosis matters. Immune-mediated hair loss requires a different approach from nutritional shedding, hair-shaft breakage, androgenetic alopecia and scarring disease.
References
- Paus R, Nickoloff BJ, Ito T. A “Hairy” Privilege. Trends in Immunology. 2005;26(1):32–40. https://doi.org/10.1016/j.it.2004.09.014
- Ito T, Ito N, Saatoff M, et al. Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack. Journal of Investigative Dermatology. 2008;128(5):1196–1206. https://doi.org/10.1038/sj.jid.5701183
- Rosenblum MD, Olasz EB, Yancey KB, et al. Expression of CD200 on Epithelial Cells of the Murine Hair Follicle: A Role in Tissue-Specific Immune Tolerance? Journal of Investigative Dermatology. 2004;123(5):880–887. https://doi.org/10.1111/j.0022-202X.2004.23461.x
- Schneider MR, Schmidt-Ullrich R, Paus R. The Hair Follicle as a Dynamic Mini-Organ. Current Biology. 2009;19(3):R132–R142. https://doi.org/10.1016/j.cub.2008.12.005
- Gilhar A, Etzioni A, Paus R. Alopecia Areata. New England Journal of Medicine. 2012;366(16):1515–1525. https://doi.org/10.1056/NEJMra1103442
- Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia Areata Update: Part I. Clinical Picture, Histopathology, and Pathogenesis. Journal of the American Academy of Dermatology. 2010;62(2):177–188. https://doi.org/10.1016/j.jaad.2009.10.032
- Guo H, Cheng Y, Shapiro J, McElwee K. The Role of Lymphocytes in the Development and Treatment of Alopecia Areata. Expert Review of Clinical Immunology. 2015;11(12):1335–1351. https://doi.org/10.1586/1744666X.2015.1085306
- Šutić Udović I, Prpić Massari L, Brajac I, et al. Deciphering the Complex Immunopathogenesis of Alopecia Areata. International Journal of Molecular Sciences. 2024;25(11):5652. https://doi.org/10.3390/ijms25115652
- Xing L, Dai Z, Jabbari A, et al. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition. Nature Medicine. 2014;20(9):1043–1049. https://doi.org/10.1038/nm.3645
- Christoph T, Müller-Röver S, Audring H, et al. The Human Hair Follicle Immune System: Cellular Composition and Immune Privilege. British Journal of Dermatology. 2000;142(5):862–873. https://doi.org/10.1046/j.1365-2133.2000.03464.x
- Paus R, Bulfone-Paus S, Bertolini M. Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management. Journal of Investigative Dermatology Symposium Proceedings. 2018;19(1):S12–S17. https://doi.org/10.1016/j.jisp.2017.10.014
- Bertolini M, McElwee K, Gilhar A, Bulfone-Paus S, Paus R. Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata. Experimental Dermatology. 2020;29(8):703–725. PubMed record
- Zhou C, Li X, Wang C, Zhang J. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management. Clinical Reviews in Allergy & Immunology. 2021;61(3):403–423. https://doi.org/10.1007/s12016-021-08883-0
- Yamaguchi HL, Yu N, Poon E. Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences. Journal of Investigative Dermatology. 2024. PubMed record
- American Academy of Dermatology Association. Alopecia Areata: Diagnosis and Treatment. AAD treatment guidance
- U.S. Food and Drug Administration. LEQSELVI (deuruxolitinib) Prescribing Information. Revised June 2026. FDA prescribing information
Medical disclaimer: This Journal article is provided for professional education and general information. It does not replace medical assessment, diagnosis or treatment. Sudden, patchy, progressive or inflammatory hair loss may require evaluation by a dermatologist. Prescription immune-modifying treatments, including JAK inhibitors, have important contraindications, warnings and monitoring requirements and must be managed by an appropriately qualified clinician.